Neuroscience
From the company's press release:
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Alzheimer Disease: Targacept's Failed Tc-1734 Phase 2b Trial
From a Targacept press release:Targacept Phase 2b Clinical Trial in Alzheimer’s Disease Does Not Show Superiority of TC-1734 Over Donepezil July 14, 2014 "Winston-Salem, NC – Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company...
- Business World: Synthetic Blood International, Inc. And Traumatic Brain Injury
From a company press release:Synthetic Blood Announces Positive Results from Traumatic Brain Injury Preclinical Study COSTA MESA, Calif.--(BUSINESS WIRE)--Oct. 24, 2005--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced that...
- Neuropsychology Assessment Of Dementia: Early Detection
From an American Psychological Association (APA) press release on 25 September 2005:PSYCHOLOGISTS FIND MORE SENSITIVE TESTS FOR PREDICTING ALZHEIMER'S AS WELL AS SUBTLE CHANGES IN COGNITION Implicit-memory tests are stronger predictors than the common...
- Business World: Neurochem's Alzhemed And Alzheimer Disease
Neurochem completes patient recruitment for North American Phase III clinical trial for Alzhemed(TM) Milestone on Schedule Tuesday July 5, 8:31 am ET LAVAL, QC, July 5 /PRNewswire-FirstCall/ - Neurochem Inc. ... announced today the completion of recruitment...
- Business World: Combinatorx And Brain Tumors
A company press release concerning an agreement to develop additional research efforts in the search for pharmaceutical treatments for brain tumors: CombinatoRx and ABC2 Initiate Brain Cancer Collaboration: Partnership Speeds Search for Brain Cancer...
Neuroscience
Business World: Everest Biomedical
From the company's press release:
Everest Biomedical Forms Research Alliance With NYU[ ... Read the full press release ... ]
ST. LOUIS, June 7 /PRNewswire/ -- Everest Biomedical Instruments Company, based in St. Louis, announced today its alliance with New York University School of Medicine's Brain Research Laboratory (BRL). The agreement provides Everest with exclusive rights to a number of patents and patent applications from the laboratory. BRL's patented information covers the fields of electroencephalography (EEG), neurodiagnostics, neurotherapy, brain function scanning and anesthesia, analgesia and amnesia monitoring. Terms of the agreement were not disclosed.
Access to BRL's intellectual property will accelerate Everest's commercialization of novel brain-state neurological assessment devices. Designed to assist physicians in screening and evaluating patients with an altered mental status, Everest's new product plans include creation of a handheld device, the BrainScope(TM), that produces automatic, functional brain-state assessments. The technology could lead to improved results and more efficient care for patients suffering from traumatic brain injuries, strokes, seizures, Alzheimer's disease and various psychiatric disorders.
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Alzheimer Disease: Targacept's Failed Tc-1734 Phase 2b Trial
From a Targacept press release:Targacept Phase 2b Clinical Trial in Alzheimer’s Disease Does Not Show Superiority of TC-1734 Over Donepezil July 14, 2014 "Winston-Salem, NC – Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company...
- Business World: Synthetic Blood International, Inc. And Traumatic Brain Injury
From a company press release:Synthetic Blood Announces Positive Results from Traumatic Brain Injury Preclinical Study COSTA MESA, Calif.--(BUSINESS WIRE)--Oct. 24, 2005--Synthetic Blood International, Inc. (OTCBB:SYBD) today announced that...
- Neuropsychology Assessment Of Dementia: Early Detection
From an American Psychological Association (APA) press release on 25 September 2005:PSYCHOLOGISTS FIND MORE SENSITIVE TESTS FOR PREDICTING ALZHEIMER'S AS WELL AS SUBTLE CHANGES IN COGNITION Implicit-memory tests are stronger predictors than the common...
- Business World: Neurochem's Alzhemed And Alzheimer Disease
Neurochem completes patient recruitment for North American Phase III clinical trial for Alzhemed(TM) Milestone on Schedule Tuesday July 5, 8:31 am ET LAVAL, QC, July 5 /PRNewswire-FirstCall/ - Neurochem Inc. ... announced today the completion of recruitment...
- Business World: Combinatorx And Brain Tumors
A company press release concerning an agreement to develop additional research efforts in the search for pharmaceutical treatments for brain tumors: CombinatoRx and ABC2 Initiate Brain Cancer Collaboration: Partnership Speeds Search for Brain Cancer...